El texto completo de este trabajo no está disponible en el Repositorio Académico UPC por restricciones de la casa editorial donde ha sido publicado. / Objective: The objective of this study was to characterize the composition of the gut microbiota in type 2 Diabetes Mellitus (T2DM) patients with adequate and inadequate metabolic control, and its relationship with fiber consumption. Results: A total of 26 patients with type 2 diabetes mellitus (T2DM) were enrolled, of which 7 (26.9%) cases had adequate metabolic control (HbA1c < 7%) and 19 (73.1%) inadequate metabolic control (HbA1c ≥ 7%). It was observed that among patients with controlled T2DM, 2 (28.6%) cases presented good intake of fiber and 5 (71.4%) cases a regular intake. In contrast, in patients with uncontrolled T2DM, 13 (68.4%) patients reported a regular intake and 6 (31.6%) a poor intake. In relation to the identification of the gut microbiota, both groups presented a similar characterization. There were differences in the population of bacteria identified in both groups, however, the results were not statistically significant. The most frequently identified bacteria in controlled and uncontrolled T2DM patients were Prevotella (71.4% vs 52.6%), followed by Firmicutes (71.4% vs 42.1%), Proteobacteria (71.4% vs 36.8%) and Bacteroidetes (57.1% vs 37.8%). On the other hand, Fusobacterium, Actinobacteria were not identified in either of the two groups of study. / Revisión por pares

Daug pasaulinių organizacijų, kurios stengiasi pagerinti cukrinio diabeto diagnostiką ir sergančių pacientų glikemijos kontrolę, nes nepakankama ir vėlyva diagnostika skatina komplikacijų atsiradimą ir progresavimą. Šio darbo tikslas išanalizuoti cukriniu diabetu sergančių pacientų metodologinių ypatumų įtaką glikozilinto hemoglobino rezultatams. Išmatavus analitę HbA1c, 100 pacientų sergančių cukriniu diabetu, trimis skirtingos standartizacijos analizinėmis sistemomis Roche-Hitachi 917, Bayer-Advia1650 ir Dade Behring-Dimension RxL, gauta koreliacija su trijų mėnesių gliukozės koncentracijos vidurkiu. Lyginant HbA1c rezultatus, referentiniu metodu Roche-Hitachi 917 analizine sistema, standartizuota Tarptautinės klinikinės chemijos ir laboratorinės medicinos federacijos (IFCC) ir Diabeto kontrolės ir komplikacijų tyrimų (DCCT), gautas skirtumas. Bayer-Advia1650 analizinė sistema, kurios HbA1c metodas standartizuotas Nacionalinės glikohemoglobino standartizacijos programos (NGSP), lyginant su mūsų referentinio metodo rezultatais, kai IFCC standartizacija r = 1.017 [0.883 iki 1.188]; y = 3.068 [1.894 iki 4.142]; n = 52; p = 0.0000001, o kai standartizacija DCCT r = 1.132 [1.060 iki 1.209]; y = 0.282 [-0.476 iki 0.990]; n = 53; p = 0.001. Dade Behring-Dimension RxL analizinės sistemos metodas standartizuotas pagal Diabeto kontrolės ir komplikacijų tyrimus (DCCT) palyginus su IFCC standartizuotu metodu rezultatais: r = 0.886 [0.767 iki 1.021]; y = 2.422 [1.630 iki 3.413]; n = 52... [toliau žr. visą tekstą] / There are many organisations trying to improve Diabetes Mellitus diagnostics, enhance glycaemia management of diabetes patients, because insufficient and late diagnosis increases formation, and complications progress. The purpose of this work was evolution of influence, of different methodological approaches to of glycated hemoglobin results. Samples of 100 patients with Diabetes Mellitus was analyzed for glucose and HbA1c. There was shown correlation between average concentration glucose‘s during three months coefficient. HbA1c was analyzed using three analytical systems of Roche-Hitachi 917, Bayer-Advia1650 and Dade Behring-Dimension RxL standardized according different standardization recommendations: International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), Diabetes Control and Complications Trial (DCCT), National Glycohemoglobin Standardization Program (NGSP). Roche-Hitachi 917 results standardized according IFCC recommendations were chosen as reference. Correlation and differences between analytical systems were as follows. Roche-Hitachi 917 (IFCC) – Bayer-Advia1650 (NGSP): r = 1.017 [0.883 to 1.188]; y = 3.068 [1.894 to 4.142]; n = 52; p = 0.0000001. Roche-Hitachi 917 (DCCT) – Bayer-Advia1650 (NGSP): r = 1.132 [1.060 to 1.209]; y = 0.282 [-0.476 to 0.990]; n = 53; p = 0.001. Roche-Hitachi 917 (IFCC) – Dade Behring-Dimension RxL (DCCT): 0.886 [0.767 to 1.021]; y = 2.422 [1.630 to 3.413]; n = 52; p = 0.0000001. Roche-Hitachi 917 (DCCT) – Dade... [to full text]